Insilico Medicine Receives FDA Fast Track Designation for AI-Driven Pan-TEAD Inhibitor ISM6331 in Advanced Mesothelioma on July 30, 2026 Chemistry42 Fast Track designation Hippo Signaling Pathway Insilico Medicine Malignant Pleural Mesothelioma pan-TEAD inhibitor United States Food and Drug Administration Unresectable +
Kelonia Therapeutics delivers impressive in vivo CAR-T update on June 01, 2026 acquisition CAR-T Eli Fast Track designation in vivo Kelonia Therapeutics MRD-negative Multiple Myeloma +